Immunotherapy in Sarcoma: A Brief Review

The systemic treatment of soft tissue sarcomas other than Gastrointestinal Stromal Tumors (GIST) has not changed for several decades. The recently demonstrated effectiveness of immune checkpoint inhibitors in melanoma has led to its application to other solid tumors with many ongoing studies that await completion. Soft tissue sarcomas possess several classes of immunogenic antigens that could provide a basis for future immunotherapy trials. The presence of Cancer Testis Antigens (CTA) and other immunogenic antigens unique to soft tissue sarcomas will be reviewed here along with a review of past studies that may shed light on the design and conduct of future immunotherapy trials in sarcoma.